PAR
Click for more information
1.96% 25.0¢ paradigm biopharmaceuticals limited..

Ann: Change of Director's Interest Notice, page-12

  1. Sojourner
    6,521 Posts.
    lightbulb Created with Sketch. 1923
    clock Created with Sketch.
    19/11/19
    18:47
    Post #: 41514925
    Most phase II trials are also for new untested drugs. They often fail because of adverse events.

    PPS is not a new drug. It's repurposed and been in use in humans for many decades.

    Given those factors the odds change dramatically in PAR's favour.
    Last edited by Sojourner: 19/11/19
    PAR Price at posting: $3.75 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 8  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

MND Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
right-arrow Created with Sketch.
AVH Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
right-arrow Created with Sketch.
POL Polymetals finalises acquisition of Endeavor silver-lead-zinc mine in NSW's Cobar Basin
right-arrow Created with Sketch.
MAG Magmatic defines 6km copper trend with grades of up to 6.5% at NSW prospect
right-arrow Created with Sketch.
LML Lincoln repositions Kookaburra for low-cost graphite delivery
right-arrow Created with Sketch.
STX Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
25.0¢ 		Change
-0.005(1.96%) 		Mkt cap ! $87.44M
Open High Low Value Volume
25.0¢ 25.5¢ 25.0¢ $13.08K 51.83K

Buyers (Bids)

No. Vol. Price($)
5 133489 25.0¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 25012 2
View Market Depth
Last trade - 16.10pm 02/08/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.